Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis.

[1]  C. Ball,et al.  Rat tumour necrosis factor-alpha: expression in recombinant Pichia pastoris, purification, characterization and development of a novel ELISA. , 1999, European cytokine network.

[2]  D. Carr,et al.  Regulation of IL-15-Stimulated TNF-α Production by Rolipram , 1999, The Journal of Immunology.

[3]  I. C. Almeida,et al.  Differential inhibitory mechanism of cyclic AMP on TNF‐α and IL‐12 synthesis by macrophages exposed to microbial stimuli , 1999, British journal of pharmacology.

[4]  F. Cunha,et al.  Pharmacological modulation of secondary mediator systems–cyclic AMP and cyclic GMP–on inflammatory hyperalgesia , 1999, British journal of pharmacology.

[5]  J. Pelletier,et al.  Effect of nimesulide on glucocorticoid receptor activity in human synovial fibroblasts. , 1999, Rheumatology.

[6]  F. Brennan,et al.  Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases. , 1998, Transplantation proceedings.

[7]  M. M. Teixeira,et al.  Effect of PDE4 inhibitors on zymosan‐induced IL‐8 release from human neutrophils: synergism with prostanoids and salbutamol , 1998, British journal of pharmacology.

[8]  T. Torphy.  Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. , 1998, American journal of respiratory and critical care medicine.

[9]  M. Feldmann,et al.  Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. , 1997, Journal of immunology.

[10]  E. Tindall,et al.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. , 1997, The New England journal of medicine.

[11]  L. Klareskog,et al.  Amelioration of collagen II‐induced arthritis in rats by the type IV phosphodiesterase inhibitor Rolipram , 1997, Clinical and experimental immunology.

[12]  M. Teixeira,et al.  Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? , 1997, Trends in pharmacological sciences.

[13]  D. Yarnall,et al.  Anti‐inflammatory activity of phosphodiesterase (PDE)‐IV inhibitors in acute and chronic models of inflammation , 1995, Clinical and experimental immunology.

[14]  D. Yarnall,et al.  Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. , 1995, The Journal of pharmacology and experimental therapeutics.

[15]  J. Klippel,et al.  Second-line drug therapy for rheumatoid arthritis. , 1994, The New England journal of medicine.

[16]  D. Trentham,et al.  Pathogenesis of rheumatoid arthritis , 1993, The Lancet.

[17]  T. Meert,et al.  Further evidence validating adjuvant arthritis as an experimental model of chronic pain in the rat. , 1982, Life sciences.

[18]  Owen Rt.  Adjuvant induced polyarthritis - an overview. , 1980 .

[19]  R. Capetola,et al.  Suprofen, a new peripheral analgesic. , 1980, The Journal of pharmacology and experimental therapeutics.

[20]  C. Pearson,et al.  Studies of arthritis and other lesions induced in rats by injection of mycobacterial adjuvant. II. Evidence that the disease is a disseminated immunologic response to exogenous antigen. , 1960, Journal of immunology.

[21]  C. Pearson.  Development of Arthritis, Periarthritis and Periostitis in Rats Given Adjuvants.∗ , 1956, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[22]  J. Francischi,et al.  Cyclosporin inhibits hyperalgesia and edema in arthritic rats: role of the central nervous system. , 1997, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.